18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

BEAM News
Member News
Events

Latest news of BEAM Alliance

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

07 January 2020 - Centauri Therapeutics Ltd

CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

The award will help Centauri continue the development of ABX01. The novel immunotherapy is in the lead optimization phase of…

06 January 2020 - Mutabilis SAS

Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines

Aleks Engel, Director of the REPAIR Impact Fund, commented: “We are thrilled to have Mutabilis and IBT Vaccines join the…

04 January 2020 - VetoPhage

Interview De VetoPhage, Labellisée French Tech Seed

Bacterial resistance to antibiotics is increasing dramatically both in animal health and in human health. So thanks to a “one…

02 January 2020 - ANTABIO S.A.S

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Antabio’s innovative PEi program seeks to develop an inhaled product to be used as an adjunct to existing therapy and…

03 December 2019 - Grit42

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

Co-founder and CEO of grit42, Claus Stie Kallesøe, adds, “The COMBINE project is an important milestone in the evolution of…

18 November 2019 - Grit42

Strengthening their commitment to help tackle antimicrobial resistance, grit42 joins the BEAM Alliance

“We’re thrilled to join the BEAM Alliance - the premier European network within the AMR community. As we’re already part…

page 1/16

Events

07 November 2019

REVIVE webinar: Converting Gram-positive-only compounds into broad-spectrum antibiotics

This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail…

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

03 October 2019

REVIVE webinar: Natural products antibiotics: from traditional screening to novel discovery approaches

In this webinar, Olga Genilloud will discuss the role of natural products in current antibiotic discovery.

02 October 2019

IDWeek 2019

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America…

26 September 2019

Institut Pasteur : Table ronde sur La résistance aux agents antimicrobiens

À l’occasion de la visite de Jim O’Neill, ancien secrétaire d’État britannique, le professeur Stewart Cole, directeur général de l’Institut…

25 September 2019

Phage Futures Europe

Translating phage-based applications into clinically and commercially viable therapeutics

10 September 2019

REVIVE webinar: Models for antimicrobial R&D: Advanced and complex in vivo models for infectious disease research

In this webinar, Peter Warn will review the experimental design and conduct of advanced or complex animal models for antimicrobial…

06 September 2019

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

This symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem…

03 September 2019

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…

page 2/4